Factors Associated with Hospitalization and Disease Severity in a Racially and Ethnically Diverse Population of COVID-19 Patients

INTRODUCTION

In December 2019, an outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pneumonia appeared in Wuhan and rapidly spread throughout the world causing more than 8 million infections and close to 450,000 deaths by June 2020.^1,2 Similar to previous coronaviruses, the newly identified virus is highly contagious; it is transmitted primarily through droplets and causes major outbreaks in the absence of adequate control measures.³ The manifestations of the coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 are widely variable. The infection is asymptomatic in some individuals, while in others, it causes symptoms ranging from dry cough and dyspnea to severe pneumonia with respiratory failure requiring admission in intensive care unit (ICU) and leading to death in severe cases.^4,5

To date, a number of studies have investigated the predictors of severe COVID-19. Nevertheless, the sociodemographic and clinical factors that influence this disease course have not been fully defined.^6-12 Whether asthma, a common respiratory illness affecting 1 in 12 American adults, is associated with disease severity in COVID-19 is still a matter of debate.^13-17 Other important clinical factors remain understudied. For example, vitamin D deficiency affects 1 in 4 American adults, has an important immunologic role and has been suggested to increase the risk of SARS-CoV-2 infection.¹⁸ However, vitamin D deficiency has not been analyzed as a risk factor for severe COVID-19 among patients infected with SARS-CoV-2. Another understudied clinical factor is hypercholesterolemia, which affects 1 in 8 American adults; whether this condition has been reported to be associated with severe COVID-19 has not been analyzed in the published literature.^19,20 Moreover, most of the research on the potential factors for severe COVID-19 have been conducted in China among Chinese patients which may limit their generalizability to multi-ethnic populations.^6-8,10 The reports that have included a racially diverse study sample are scant^9,11,12,21 To address this gap in the literature, we aimed to determine the factors associated with hospitalization and disease severity in a racially and ethnically diverse population of COVID-19 patients by including some comorbidities missing in previous studies.

METHODS

RESULTS

DISCUSSION

In this racially and ethnically diverse study population of COVID-19 patients, the sociodemographic characteristics associated with hospitalization and/or disease severity included older age, non-Hispanic Black or Hispanic race/ethnicity (compared to non-Hispanic Whites). Among the studied comorbidities, diabetes, pure hypercholesterolemia, asthma, COPD, chronic kidney disease, cardiovascular disease, osteoarthritis, and vitamin D deficiency were risk factors associated with hospitalization and/or severe COVID-19. Hematological disorders such as anemia, coagulation defects, and thrombocytopenia were associated with increased odds of both hospitalization and disease severity.

This report is one of a few epidemiological studies investigating the risk factors for disease severity in a racially and ethnically diverse sample of COVID-19 patients. In the UK, three studies analyzed data from the national Biobank and, consistent with our findings on non-Hispanic Blacks, found excess hospitalizations in Blacks and Asians compared to Whites.^23-25 In the US, five studies conducted among hospitalized COVID-19 patients observed an overrepresentation of non-Hispanic Blacks, with prevalences ranging from 51.0% to 83.2%.^9,12,25-27 However, the studies found that non-Hispanic Blacks were not at higher risk of severe disease or death compared to non-Hispanic Whites among hospitalized COVID-19 patients.^9,12,26-28 A large U.S. Department of Veterans Affairs study with 5,630 COVID-19 patients reported that non-Hispanic Blacks and Hispanics were more likely to test positive for COVID-19 than non-Hispanic Whites, but were not at higher risk of 30-day mortality.²⁰ Of all of these studies, only one examined length of hospital stay as an outcome and it found no difference by race or ethnicity.¹² Our results also suggested that although non-Hispanic Blacks and Hispanics were more likely to be hospitalized and to have severe COVID-19 than non-Hispanic Whites, length of hospital stay was not different between non-Hispanic Whites and non-Hispanic Blacks. It was even shorter in Hispanics and patients of ‘Other’ race/ethnicity than in non-Hispanic Whites. It is possible that the higher death rates in non-Hispanic Blacks could have affected the length of hospital stay and explained the non-significant difference with non-Hispanic whites. It is unclear, however why hospital stay was shorter in Hispanics and patients of ‘Other’ race/ethnicity.

Our results confirmed previous reports that older age and smoking as well as comorbidities such as diabetes, cardiovascular diseases, chronic kidney, COPD, coagulation defect, and thrombocytopenia are associated with hospitalization and/or severe COVID-19.^6,9,27,29,30 Consistent with the longer length of hospital stay noted in men in our analysis, it has been suggested that male sex may predispose to more severe COVID-19 due to hormonal factors.^11,26 Males are known to have higher activity of angiotensin-converting enzymes 2 (ACE2), the receptors of which serve as an entry point for the SARS-CoV-2 in the alveolar epithelial cells and this could explain the increased risk of infection and disease severity in men previously reported in the literature.³¹ Another hypothesis attributes the sex difference in COVID-19 severity to the transmembrane protease serine 2 (TMPRSS2) gene that is influenced by androgen/estrogen stimulation and facilitates the fusion of the viral and cellular membranes.³²

Although we found no association between obesity and severe COVID-19, other studies observed that morbid obesity (body mass index ≥40) was a risk factor of disease severity.^11,27 With regards to patients with neoplasm or a history of neoplasm, they were not found to have higher COVID-19 severity in our study. One Chinese study performed on 1,590 COVID-19 cases observed that the 18 patients with a history of cancer had a higher risk of disease severity in their crude analysis.³² However, these patients were older (63.1 years versus 48.7 years) and more likely to have been smokers (22% versus 7%) than the COVID-19 patients without a cancer history.³³ A recent meta-analysis summarizing the existing literature on cancer and COVID-19 severity concluded that the current evidence on this association remains inconclusive.³⁴ Likewise, the evidence of an association between asthma and COVID-19 severity is scarce and the previous studies were underpowered as they included few asthma cases among COVID-19 patients.^6,15 Consistent with our findings, a recent analysis of UK biobank data concluded that asthma was associated with severe COVID-19 among 641 infected patients and that this association was driven by non-allergic asthma.¹⁷

Our epidemiological study is also the first to investigate the association of conditions such as vitamin D deficiency, pure hypercholesterolemia, osteoarthritis, and anemia with severe COVID-19 An analysis of UK biobank data examined the serum levels of vitamin D and the risk of infection with COVID-19 and found no association, while another study from the University of Chicago showed an increased risk of COVID-19 infection associated with vitamin D deficiency.^18,35 However, none of the studies investigated the association of vitamin D with disease severity among patients who were already infected with SARS-CoV-2.^18,35 In an ecological study, mortality rates among COVID-19 patients were compared among developed nations and it was suggested that countries with higher prevalence of vitamin D deficiency had higher mortality rates.³⁶ Yet, ecological studies do not include patient-level data and suffer from ecological fallacy, which is the assumption that factors associated with the national disease rates are associated with disease in individual patients.³⁷ Nevertheless, there is reason to investigate Vitamin D status as a factor in disease progression. Vitamin D is well-known for its immunoregulatory properties; it can increase cellular immunity by stimulating antimicrobial peptides and could oppose cytokine storms induced by the innate immune responses.^38,39 No published epidemiological study has also investigated whether high cholesterol is associated with higher risk of COVID-19 severity, although hypercholesterolemia is a major contributor to atherosclerosis and cardiovascular disease, which itself, is associated with severe COVID-19.⁴⁰ Furthermore, high cholesterol might enhance the replication of SARS-CoV-2 in endothelial cells potentially causing acute vascular injury and triggering coagulopathies.⁴¹ No study has also examined the relationship of osteoarthritis and anemia with severe COVID-19. Osteoarthritis is a common joint disease, particularly prevalent in older adults; it is associated with various comorbidities and with an increased risk of mortality from cardiovascular diseases, diabetes and renal diseases.^42,43 Anemia affects 5.6% of all Americans, but this prevalence is increased to more than 10% in Americans aged 65 or older.^44,45 It is well-known to be a factor for poor prognosis in respiratory diseases such as COPD.⁴⁶ In our study however, it is unclear whether anemia is a factor for severe COVID-19 or a consequence of the inflammation and cytokine production caused by the infection and leading to hemolytic anemia.⁴⁶

Our study has limitations. It included only patients from a single health system in the Midwest of the U.S. and may not be generalizable to the overall American population. Our study design was observational; therefore, temporality and causality between certain factors (anemia, coagulation defects, and thrombocytopenia for instance) and COVID-19 severity cannot be established. Smoking status was missing for 22.8% of the COVID-19 participants. Vitamin D deficiency was defined using electronic medical records and data on the serum vitamin D levels were not available. Nonetheless, our study has major strengths, it was conducted in a large and racially/ethnically diverse sample of COVID-19 patients. It also included factors formerly understudied in COVID-19 such as vitamin D deficiency, pure hypercholesterolemia, osteoarthritis, and anemia.

In conclusion, the present study confirms previous reports that older age, non-Hispanic Black or Hispanic race/ethnicity, smoking, diabetes, COPD, chronic kidney disease, cardiovascular disease, coagulation defects, and thrombocytopenia are associated with severe COVID-19. It also identifies severe COVID-19 factors not previously reported such as vitamin D deficiency, pure hypercholesterolemia, osteoarthritis, and anemia. Our results are of public health relevance and have implications in the prioritization of COVID-19 patients at risk of severe disease and in the implementation of interventions to mitigate negative outcomes. Future studies should also evaluate whether vitamin D supplementation in COVID-19 patients with vitamin D deficiency might improve disease prognosis.